Other OTC - Delayed Quote USD

Navidea Biopharmaceuticals, Inc. (NAVB)

0.0381

+0.0005

(+1.33%)

At close: April 26 at 1:08 PM EDT

Navidea Biopharmaceuticals, Inc. Files Form 15 to Voluntarily Deregister and Suspend its SEC Reporting Obligations

COLUMBUS, Ohio, January 27, 2024--Navidea Biopharmaceuticals, Inc. Files Form 15 to Voluntarily Deregister and Suspend its SEC Reporting Obligations

Business Wire 2 months ago

NAVB
+1.33%
Navidea Biopharmaceuticals, Inc. and Capital Royalty Partners II, L.P. Enter Binding Settlement Agreement and Mutual Release

DUBLIN, Ohio, December 01, 2023--Navidea Biopharmaceuticals, Inc. and Capital Royalty Partners II, L.P. Enter Binding Settlement Agreement and Mutual Release

Business Wire 4 months ago

NAVB
+1.33%
Navidea Biopharmaceuticals, Inc. Announces NYSE American’s Decision to Suspend Trading In Its Common Stock

DUBLIN, Ohio, October 06, 2023--Navidea Biopharmaceuticals, Inc. Announces NYSE American’s Decision to Suspend Trading In Its Common Stock

Business Wire 6 months ago

NAVB
+1.33%
Navidea Biopharmaceuticals, Inc. NAVB Requests Oral Hearing With NYSE Hearing Panel

DUBLIN, Ohio, August 10, 2023--Navidea Biopharmaceuticals, Inc. NAVB Requests Oral Hearing With NYSE Hearing Panel

Business Wire 8 months ago

NAVB
+1.33%
Navidea Biopharmaceuticals, Inc. Presses Ahead, Embraces Opportunities

DUBLIN, Ohio, July 31, 2023--Navidea Biopharmaceuticals, Inc. Presses Ahead, Embraces Opportunities.

Business Wire 8 months ago

NAVB
+1.33%
Navidea Biopharmaceuticals, Inc. Announces NYSE American Has Commenced Delisting Proceedings and Intent to Appeal NYSE American Determination

DUBLIN, Ohio, July 29, 2023--Navidea Biopharmaceuticals, Inc. Announces NYSE American Has Commenced Delisting Proceedings and Intent to Appeal NYSE American Determination.

Business Wire 8 months ago

NAVB
+1.33%
Navidea Biopharmaceuticals, Inc. Hires Craig A. Dais, CPA as Chief Financial Officer

DUBLIN, Ohio, July 27, 2023--Navidea Biopharmaceuticals, Inc. Hires Craig A. Dais, CPA as Chief Financial Officer

Business Wire 8 months ago

NAVB
+1.33%
Navidea Biopharmaceuticals, Inc. Welcomes Dana J Moss, JD to Board of Directors; Amit Bhalla Steps Down

DUBLIN, Ohio, July 13, 2023--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced Dana J Moss, JD has joined the Company’s Board of Directors, adding depth in legal advice, strategic business, life sciences and technology in line with Navidea’s stated objectives and its Fix, Fund, Propel approach to advancing innovative technology to market. Separately

Business Wire 9 months ago

NAVB
+1.33%
Navidea Biopharmaceuticals, Inc. Rejects Unsolicited Offer To Acquire Certain Assets

DUBLIN, Ohio, June 30, 2023--Following the Company’s Fix, Fund, Propel approach, the proposal substantially undervalues Navidea and is not in the best interests of stockholders.

Business Wire 9 months ago

NAVB
+1.33%
Navidea Biopharmaceuticals, Inc. Announces Distribution of Series K Preferred Stock to Holders of its Common Stock

DUBLIN, Ohio, June 16, 2023--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that its Board of Directors declared a dividend of one one-thousandth of a share of newly designated Series K Preferred Stock, par value $0.001 per share, for each outstanding share of the Company’s common stock held of record as of 5:00 p.m. Eastern Time on June 27, 2023

Business Wire 10 months ago

NAVB
+1.33%
Navidea Biopharmaceuticals, Inc. Receives $7.5 Million Cash from Cardinal Health in Lieu of Contingent Milestone Payment

DUBLIN, Ohio, June 16, 2023--Navidea Biopharmaceuticals, Inc. Receives $7.5 Million Cash from Cardinal Health in Lieu of Contingent Milestone Payment.

Business Wire 10 months ago

NAVB
+1.33%
Navidea Biopharmaceuticals, Inc. Reports First Quarter 2023 Financial Results and Provides Business Update

DUBLIN, Ohio, June 07, 2023--Navidea Biopharmaceuticals, Inc. Reports First Quarter 2023 Financial Results and Provides Business Update

Business Wire 10 months ago

NAVB
+1.33%
Navidea Biopharmaceuticals, Inc. Receives NYSE American Notice

DUBLIN, Ohio, June 02, 2023--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that it received a Notice (the "Notice") on June 1, 2023 from the NYSE American LLC (the "NYSE American") stating that the Company is not in compliance with the continued listing standards as set forth in Section 1003(f)(v) of the NYSE American Company Guide ("Company Gui

Business Wire 10 months ago

NAVB
+1.33%
Navidea Biopharmaceuticals, Inc. Welcomes Jill Bieker Stefanelli, Ph.D. to Board of Directors; Alexander L. Cappello Steps Down

DUBLIN, Ohio, June 01, 2023--Navidea Biopharmaceuticals, Inc. Welcomes Jill Bieker Stefanelli, Ph.D. to Board of Directors; Alexander L. Cappello Steps Down.

Business Wire 10 months ago

NAVB
+1.33%
Navidea Biopharmaceuticals, Inc. Investors Purchase $1.1 Million in Preferred Shares at Market

DUBLIN, Ohio, May 22, 2023--New Existing Navidea Biopharmaceuticals, Inc. Investors Purchase $1.1 Million in Preferred Shares at Market

Business Wire 10 months ago

NAVB
+1.33%
Navidea Biopharmaceuticals, Inc. Promotes Michael Sherman Blue, M.D., FACEP, to Chief Medical Officer

DUBLIN, Ohio, May 11, 2023--Navidea Biopharmaceuticals, Inc. Promotes Michael Sherman Blue, M.D., FACEP, to Chief Medical Officer.

Business Wire 11 months ago

NAVB
+1.33%
Navidea Biopharmaceuticals, Inc. Drives Strategy Forward, Shifts Approach for Communications

DUBLIN, Ohio, May 08, 2023--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced the introduction of a Fix, Fund, Propel approach to driving the Company’s strategy forward; The Company will issue a press release detailing financial highlights and corporate developments in lieu of hosting conference call and webcast for the first quarter ended March 31s

Business Wire 11 months ago

NAVB
+1.33%

Performance Overview

Return	NAVB	S&P 500
YTD	-30.98%	+6.92%
1-Year	-84.76%	+25.26%
3-Year	-97.68%	+22.00%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Navidea Biopharmaceuticals, Inc. (NAVB)

Navidea Biopharmaceuticals, Inc. Files Form 15 to Voluntarily Deregister and Suspend its SEC Reporting Obligations

Navidea Biopharmaceuticals, Inc. and Capital Royalty Partners II, L.P. Enter Binding Settlement Agreement and Mutual Release

Navidea Biopharmaceuticals, Inc. Announces NYSE American’s Decision to Suspend Trading In Its Common Stock

Navidea Biopharmaceuticals, Inc. NAVB Requests Oral Hearing With NYSE Hearing Panel

Navidea Biopharmaceuticals, Inc. Presses Ahead, Embraces Opportunities

Navidea Biopharmaceuticals, Inc. Announces NYSE American Has Commenced Delisting Proceedings and Intent to Appeal NYSE American Determination

Navidea Biopharmaceuticals, Inc. Hires Craig A. Dais, CPA as Chief Financial Officer

Navidea Biopharmaceuticals, Inc. Welcomes Dana J Moss, JD to Board of Directors; Amit Bhalla Steps Down

Navidea Biopharmaceuticals, Inc. Rejects Unsolicited Offer To Acquire Certain Assets

Navidea Biopharmaceuticals, Inc. Announces Distribution of Series K Preferred Stock to Holders of its Common Stock

Navidea Biopharmaceuticals, Inc. Receives $7.5 Million Cash from Cardinal Health in Lieu of Contingent Milestone Payment

Navidea Biopharmaceuticals, Inc. Reports First Quarter 2023 Financial Results and Provides Business Update

Navidea Biopharmaceuticals, Inc. Receives NYSE American Notice

Navidea Biopharmaceuticals, Inc. Welcomes Jill Bieker Stefanelli, Ph.D. to Board of Directors; Alexander L. Cappello Steps Down

Navidea Biopharmaceuticals, Inc. Investors Purchase $1.1 Million in Preferred Shares at Market

Navidea Biopharmaceuticals, Inc. Promotes Michael Sherman Blue, M.D., FACEP, to Chief Medical Officer

Navidea Biopharmaceuticals, Inc. Drives Strategy Forward, Shifts Approach for Communications

Performance Overview